Infections associated with immunosuppressants - Revision history

Aidan at 14:41, 28 January 2022

2022-01-28T14:41:52Z

← Older revision		Revision as of 14:41, 28 January 2022
Line 1:		Line 1:
	{\| class="wikitable"		{\| class="wikitable sortable"
	!Drug		!Drug
	!Target		!Target

Aidan: Text replacement - "[[Human herpesviruses" to "[[Herpesviridae"

2020-09-18T17:39:23Z

Text replacement - "[[Human herpesviruses" to "[[Herpesviridae"

← Older revision		Revision as of 17:39, 18 September 2020
Line 8:		Line 8:
	\|CD52		\|CD52
	\|depletes T and B cells		\|depletes T and B cells
	\|[[~~Human herpesviruses~~\|herpesviruses]], especially [[CMV]] and [[EBV]], [[BK virus]], [[PML]], [[Pneumocystis]], [[Cryptococcus]], [[dimorphic fungi]]		\|[[Herpesviridae\|herpesviruses]], especially [[CMV]] and [[EBV]], [[BK virus]], [[PML]], [[Pneumocystis]], [[Cryptococcus]], [[dimorphic fungi]]
	\|-		\|-
	\|[[rituximab]]		\|[[rituximab]]
Line 18:		Line 18:
	\|CD3		\|CD3
	\|depletes T cells		\|depletes T cells
	\|[[~~Human herpesviruses~~\|herpesviruses]], especially [[CMV]] and [[EBV]], [[BK virus]], [[Pneumocystis]], [[Cryptococcus]], [[dimorphic fungi]]		\|[[Herpesviridae\|herpesviruses]], especially [[CMV]] and [[EBV]], [[BK virus]], [[Pneumocystis]], [[Cryptococcus]], [[dimorphic fungi]]
	\|-		\|-
	\|corticosteroids		\|corticosteroids
	\|multiple		\|multiple
	\|multiple		\|multiple
	\|[[LTBI]] reactivation, [[~~Human herpesviruses~~\|herpesviruses]] (especially [[HSV]]/[[VZV]]), [[Candida]], [[Pneumocystis]], [[dimorphic fungi]], [[invasive fungal infection]]		\|[[LTBI]] reactivation, [[Herpesviridae\|herpesviruses]] (especially [[HSV]]/[[VZV]]), [[Candida]], [[Pneumocystis]], [[dimorphic fungi]], [[invasive fungal infection]]
	\|-		\|-
	\|[[adalimumab]]		\|[[adalimumab]]

Aidan at 19:55, 11 September 2020

2020-09-11T19:55:27Z

← Older revision		Revision as of 19:55, 11 September 2020
Line 75:		Line 75:
	\|inhibits terminal complement		\|inhibits terminal complement
	\|severe [[Neisseria meningitidis]] infections, [[Streptococcus pneumoniae]], [[Haemophilus influenzae]]		\|severe [[Neisseria meningitidis]] infections, [[Streptococcus pneumoniae]], [[Haemophilus influenzae]]
			\|-
			\|[[ustekinumab]]
			\|IL-12 and IL-23
			\|inhibits cytokines
			\|
	\|}		\|}

Aidan: Created page with "{| class="wikitable" !Drug !Target !Effect !Infections |- |alemtuzumab |CD52 |depletes T and B cells |herpesviruses, especially CMV and EBV..."

2020-09-11T19:45:22Z

Created page with "{| class="wikitable" !Drug !Target !Effect !Infections |- |alemtuzumab |CD52 |depletes T and B cells |herpesviruses, especially CMV and EBV..."

New page

{| class="wikitable"
!Drug
!Target
!Effect
!Infections
|-
|[[alemtuzumab]]
|CD52
|depletes T and B cells
|[[Human herpesviruses|herpesviruses]], especially [[CMV]] and [[EBV]], [[BK virus]], [[PML]], [[Pneumocystis]], [[Cryptococcus]], [[dimorphic fungi]]
|-
|[[rituximab]]
|CD20
|depletes B cells
|[[HBV]] reactivation, [[PML]], [[Pneumocystis]]
|-
|[[antithymocyte globulin]]
|CD3
|depletes T cells
|[[Human herpesviruses|herpesviruses]], especially [[CMV]] and [[EBV]], [[BK virus]], [[Pneumocystis]], [[Cryptococcus]], [[dimorphic fungi]]
|-
|corticosteroids
|multiple
|multiple
|[[LTBI]] reactivation, [[Human herpesviruses|herpesviruses]] (especially [[HSV]]/[[VZV]]), [[Candida]], [[Pneumocystis]], [[dimorphic fungi]], [[invasive fungal infection]]
|-
|[[adalimumab]]
| rowspan="4" |TNF-α
| rowspan="4" |
| rowspan="4" |intracellular organisms, including [[tuberculosis]], [[non-tuberculous mycobacteria]], [[Aspergillus]], [[dimorphic fungi]], [[Pneumocystis]], [[Cryptococcus]], [[Candida]], [[hepatitis B]], [[human herpesviruses]] (especially [[HSV]] and [[VZV]]), [[Strongyloides stercoralis]], [[Legionella]], [[Nocardia]], [[Salmonella]], [[Staphylococcus aureus]] septic arthritis, [[Leishmania]], [[Plasmodium]], [[Babesia]], [[Strongyloides]]
|-
|[[infliximab]]
|-
|[[golimumab]]
|-
|[[etanercept]]
|-
|[[anakinra]]
| rowspan="3" |IL-1
| rowspan="3" |prevents cytokines from activating B and T cells
| rowspan="3" |[[LTBI]] reactivation
|-
|[[canakinumab]]
|-
|[[rilonacept]]
|-
|[[basiliximab]]
| rowspan="2" |CD-25
| rowspan="2" |block IL-2 receptor, preventing activation of T, B, and NK cells
| rowspan="2" |[[human herpesviruses]]
|-
|[[daclizumab]]
|-
|[[tocilizumab]]
|IL-6
|prevents cytokine production
|[[LTBI]] reactivation, [[Candida]], [[Aspergillus]], [[Pneumocystis]], [[dimorphic fungi]], [[human herpesviruses]]
|-
|[[abatacept]]
| rowspan="2" |CD28
| rowspan="2" |blocks APCs from binding T cells
| rowspan="2" |[[EBV]], [[PML]], [[CMV]], [[Pneumocystis]], [[LTBI]] reactivation, [[hepatitis B]] reactivation, malignancies ([[lymphoma]], [[lung cancer]], and [[skin cancer]])
|-
|[[belatacept]]
|-
|[[natalizumab]]
| rowspan="2" |integrin
| rowspan="2" |inhibits T cell migration
| rowspan="2" |
|-
|[[vedolizumab]]
|-
|[[eculizumab]]
|C5
|inhibits terminal complement
|severe [[Neisseria meningitidis]] infections, [[Streptococcus pneumoniae]], [[Haemophilus influenzae]]
|}